The new type of amperometric biosensor described herein, which was fabricated by using a track-etched microporous membrane electrode for glucose detection, comprises a prereactor electrode, a detector electrode, and an immobilized enzyme reactor sandwiched between these electrodes. Because the sample solution flows through this system, the interferents are electrolyzed completely at the prereactor, positioned upstream of the enzyme reactor. The increased current response at the detector electrode derives solely from oxidation of hydrogen peroxide produced in the enzymatic reaction. Sensitive and selective response toward glucose detection was obtained with no other catalytic material such as peroxidase or an electron mediator.
Dupilumab is a humanized monoclonal antibody against the interleukin (IL)-4 receptor alpha chain that inhibits IL-4 and IL-13 signalling. It is one of the systemic treatments for patients with moderate-to-severe atopic dermatitis (AD), which provides favourable safety and efficacy. We report a case of psoriasis-like eruption induced by dupilumab as an adverse effect in a patient with AD, immediately remitted after switching to baricitinib, which inhibits JAK1/2. Moreover, the atopic skin lesion also simultaneously went into remission upon baricitinib treatment. Baricitinib could be a favourable option for patients with AD who develop dupilumab-induced psoriasis-like eruption.